[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@awakn_ls](/creator/twitter/awakn_ls)
"Solvonis is advancing SVN002 under the FDAs 505(b)(2) pathway referencing J&Js $1B+ blockbuster Spravato. SVN002 targets moderate-to-severe #AUD with a differentiated formulation for addiction clinics. #SVN002 #505b2 #Spravato #AddictionTreatment #Solvonis $SVNS"  
![@awakn_ls Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1265596823818907648.png) [@awakn_ls](/creator/x/awakn_ls) on [X](/post/tweet/1946140765886800278) 2025-07-18 09:31:30 UTC 8583 followers, XXX engagements


"AUD is the crisis we keep ignoring 29.5M Americans meet criteria for AUD X% get treatment. SVN002 is our neuroscience-led response: ✔ Novel esketamine therapeutic ✔ Clinic-based ✔ 505(b)(2) path bridging to Spravato #AUD #SVN002 #505b2 #AddictionTreatment #Solvonis"  
![@awakn_ls Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1265596823818907648.png) [@awakn_ls](/creator/x/awakn_ls) on [X](/post/tweet/1945051660654350619) 2025-07-15 09:23:47 UTC 8581 followers, XXX engagements


"Congrats to @SolvonisTx Chair Dennis Purcell on landmark $1.9B @AbbVieIGI deal As a Board Director at IGI he played a key role in one of biotechs biggest licensing agrmnts of 2025 🔹$700M upfront 🔹$1.225B in milestones 🔹Tiered royalties Proud to have him lead Solvonis"  
![@awakn_ls Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1265596823818907648.png) [@awakn_ls](/creator/x/awakn_ls) on [X](/post/tweet/1944672838041960452) 2025-07-14 08:18:29 UTC 8581 followers, XXX engagements